Published: 29 Jun 2017
Pacific Radiology Wellington and Canterbury now have access to a PET radiopharmaceutical that will help optimise management of prostate cancer patients.
This new tracer is PSMA (prostate-specific membrane antigen). PSMA PET imaging in prostate cancer is very sensitive in detection of nodal and other metastatic disease. Recently several studies have shown the potential of PSMA PETCT for initial staging, including lymph node staging. Detection of post-treatment disease recurrence, even at very low PSA levels, is also an important application for PSMA.
The addition of PSMA PETCT imaging complements the multi-parametric 3T prostate MRI service that is currently available at the Bowen Centre in Wellington. 3T MRI is the gold standard assessment for tumour staging in the prostate gland.
|18F-PSMA PETCT scan, axial fused image showing focal uptake in the prostate gland.
||18F-PSMA PETCT scan, axial fused image showing focal uptake in a para-aortic lymph node.
||18F-PSMA PETCT scan, axial fused image showing focal uptake in an L5 bone metastasis.
Advantages of 18F-PSMA PETCT Imaging
- PETCT with 18F-PSMA is sensitive for detection of prostate cancer even when PSA level is low.
- 18F-PSMA PETCT is excellent for restaging in recurrence/biochemical failure after definitive treatment of prostate cancer.
- PETCT is a hybrid imaging technique combining functional and anatomical information.
- 18F-PSMA PETCT enhances diagnostic accuracy and is increasingly used as a staging tool in prostate cancer and in patients with suspicion of recurrent disease.
From January 2017, Southern Cross Health Insurance now fully fund 18F-PSMA PETCT scans.
Please contact one of our PETCT radiologists should you wish to discuss PSMA PETCT for one of your patients.
Pru Burns, Charge Nuclear Medicine & PET Technologist
References: Dietlein et al. Comparison of 18F-DCFPyl and 68Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate cancer; Mol Imaging Bio, 2016; 17:575-584